Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093470 · ClinicalTrials.gov registry record · Phase 3
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 144
- Enrollment target
NCT00093470: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00093470 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 144 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00093470, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 144 participants
- Enrollment target
Study Summary
This randomized phase III trial studies tipifarnib in treating patients with acute myeloid leukemia (AML) in remission. Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It is not yet known whether tipifarnib is more effective than observation alone in preventing the recurrence of AML.
Interventions
- DRUG Tipifarnib
- PROCEDURE Clinical Observation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2004-08-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00093470
The ClinicalTrials.gov registry entry for NCT00093470 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tipifarnib is the first listed.
NCT00093470 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00093470 about?
NCT00093470 is a clinical study titled "Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission". This randomized phase III trial studies tipifarnib in treating patients with acute myeloid leukemia (AML) in remission. Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It is not yet known whether tipifarnib is more effective than observation alone i...
What is the current status of trial NCT00093470?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 144 participants. The study started on 2004-08-18.
What interventions are being tested in trial NCT00093470?
The interventions under investigation include: Tipifarnib (DRUG), Clinical Observation (PROCEDURE).
Who is sponsoring clinical trial NCT00093470?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.